Results 41 to 50 of about 3,564 (173)

Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis

Hepatology Communications, 2023
The cystic fibrosis (CF) transmembrane conductance regulator corrector/potentiator combinations lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor improve sweat chloride, pulmonary function, and nutrition.
Steven Levitte, Yonathan Fuchs, Russell Wise, Zachary M. Sellers   +3 more
doaj   +1 more source

Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor [case report]. [PDF]

, 2022
Before the arrival of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators women with CF and impaired lung function were experiencing a high risk of complications and mortality during and the years after pregnancy.
Jesica Mazza Stalder, Koutsokera, A., Mitropoulou, Georgia, David Baud, Baud, D., Panchaud, A., Baud, David, Faure van Rossum, A., Mitropoulou, G., Alice Panchaud, Koutsokera, Angela, Georgia Mitropoulou, Angela Koutsokera, Faure van Rossum, Annabelle, Balmpouzis, Zisis, Panchaud, Alice, Annabelle Faure van Rossum, Mazza Stalder, Jesica, Balmpouzis, Z., Mazza Stalder, J., Zisis Balmpouzis   +20 more
core   +1 more source

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe

Frontiers in Pharmacology, 2021
Objectives: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Kalydeco® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and Symkevi® (tezacaftor/ivacaftor), have substantially improved patients’ lives yet significantly burden healthcare
Khadidja Abdallah, Kris De Boeck, Marc Dooms, Steven Simoens   +3 more
doaj   +1 more source

No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.

, 2022
In this case report the potential drug-drug interaction between cytochrome P450 (CYP) 3A4 substrates tezacaftor-ivacaftor and CYP3A4/5 inhibitor clofazimine is investigated in a patient with cystic fibrosis.
Terheggen-Lagro, S. W. J., Mouissie, L. M., Kemper, E. M., Mathôt, R. A. A., Vonk, S. E. M.   +4 more
core   +1 more source

Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis

, 2021
OBJECTIVES: Tobacco smoke exposure reduces CFTR functional expression in vitro and contributes to acquired CFTR dysfunction. We investigated whether it also inhibits the clinical benefit of CFTR modulators, focusing on tezacaftor/ivacaftor, approved in ...
Elizabeth Baker, Steven M. Rowe, Harris, William T., Gabriela R. Oates, Sarah B. Rutland, Rutland, Sarah B., William T. Harris, Oates, Gabriela R., Baker, Elizabeth, Rowe, Steven M.   +9 more
core   +1 more source

VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles

, 2018
BACKGROUND : VX-445 is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function in patients with cystic fibrosis when administered with tezacaftor and ivacaftor (VX-445 ...
Moskowitz, Samuel M, Ramsey, Bonnie W, Tullis, Elizabeth, Van Goor, Fredrick, Young, Tim, VX16-445-001 study group, for the, Marigowda, Gautham, Robertson, Sarah, Van Braeckel, Eva, McKee, Charlotte M, Mall, Marcus A, Taylor-Cousar, Jennifer L, Rowe, Steven M, Simard, Christopher, Waltz, David, Xuan, Fengjuan, Keating, Dominic, Burr, Lucy, Savage, Jessica, McKone, Edward F, Daines, Cori, Sass, Laura A   +21 more
core   +2 more sources

Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis

Pharmacogenomics and Personalized Medicine, 2022
Iram Haq,1,2 Maryam Almulhem,1 Simone Soars,1 David Poulton,2,3 Malcolm Brodlie1,2 1Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; 2Paediatric Respiratory Medicine, Great North ...
Haq I, Almulhem M, Soars S, Poulton D, Brodlie M   +4 more
doaj  

Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome

Microbiology Spectrum, 2023
People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF.
Ryan Marsh, Claudio Dos Santos, Liam Hanson, Christabella Ng, Giles Major, Alan R. Smyth, Damian Rivett, Christopher van der Gast   +7 more
doaj   +1 more source

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial

, 2022
Background: Elexacaftor plus tezacaftor plus ivacaftor is a triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimen shown to be generally safe and efficacious in people with cystic fibrosis aged 12 years or older ...
Moskowitz, Samuel M., Ahluwalia, Neil, Peckham, Daniel, Lee, Timothy, Lorenz, Michael, Hilliard, Tom, Vanderhelst, Eef, Duckers, Jamie, Verhulst, Stijn, Van Braeckel, Eva, McKone, Edward F., Bruinsma, Bote G., Thursfield, Rebecca, van Koningsbruggen-Rietschel, Silke, Harris, Christopher, Gleiber, Wolfgang, Stehling, Florian, Vermeulen, Francois, Lou, Yiyue, Downey, Damian G., Aurora, Paul, Wark, Peter, Fischer, Rainald, Nash, Edward F., Mall, Marcus A., Gray, Robert, Tullis, Elizabeth, Lam, Anna P., Roehmel, Jobst, Haworth, Charles, Withers, Nicholas John, Tian, Simon, Barry, Peter, Watson, Danie, Robinson, Philip J., Yuan, Jason, Legg, Julian, Waltz, David, Sutharsan, Sivagurunathan, Mulrennan, Siobhain A., Clements, Barry S., Naehrig, Susanne, Wainwright, Claire E., Doe, Simon James, Smith, Daniel J., MacGregor, Gordon, Barr, Helen Louise   +46 more
core   +1 more source

A rapid RP-HPLC method for the simultaneous estimation of Ivacaftor and Tezacaftor and in silico study of their metabolitic products

Future Journal of Pharmaceutical Sciences, 2021
Background This study was designed to develop a reliable method for estimation of Ivacaftor and Tezacaftor in pure and its pharmaceutical dosage form by RP-HPLC in human plasma.
Madhuri Donakonda, Srija Indrakanti, Praveen Kumar Pasala, Malleswari Desari, Shireesha Kammari   +4 more
doaj   +1 more source